FDA issues warning on PPI, H2 blocker antacids: May increase risk of CDAD
SILVER SPRING, Md. — The Food and Drug Administration on Wednesday issued a public warning that the use of proton-pump inhibitors or H2 blockers may be associated with an increased risk of Clostridium difficile–associated diarrhea, or CDAD.
Patients should immediately contact their healthcare professional and seek care if they take PPIs and develop diarrhea that does not improve, the agency stated.
Clostridium difficile is a bacterium that can cause diarrhea that does not improve. Symptoms include watery stool, abdominal pain and fever, and patients may go on to develop more serious intestinal conditions. The disease also can be spread in the hospital. Factors that may predispose an individual to developing CDAD include advanced age, certain chronic medical conditions and taking broad spectrum antibiotics. Treatment for CDAD includes the replacement of fluids and electrolytes and the use of special antibiotics.
The FDA is working with manufacturers to include information about the increased risk of CDAD with use of PPIs in the drug labels, the agency said.
To review the safety announcement, and for a full list of both prescription and over-the-counter brands included in the warning, click here.
No comments found
Walgreens direct messaging those social consumers ‘checking in’ at its stores
NEW YORK — Walgreens in January has been utilizing a new mobile advertising tool to push out messages targeting consumers who just "checked in" at one of its locations, according to a report published in Ad Age Wednesday.
According to the report, Walgreens sent out 5,000 messages in January via Twitter stating: "Check out Halls’ new cough drops in the cold aisle."
The tool is startup LocalResponse, and Walgreens is credited with being the first retailer to use the new service to publish deals or promotions for consumer packaged goods. Walgreens has an exclusive with LocalResponse for one year, the report added.
No comments found
SpermCheck Fertility introduced online, in stores this spring
CHARLOTTESVILLE, Va. — A new at-home test that analyzes a male’s sperm count has entered the market.
SpermCheck Fertility is an at-home, noninvasive screening test for men that’s designed to determine "normal" to "low" sperm count with 98% accuracy, according to the manufacturer. The 10-minute test indicates if sperm count is within “normal” range (at or above 20 million sperm per mL, which is the accepted standard for normal sperm count) or "low," which would indicate that a visit to the physician for further analysis of the man is in order. Currently available online at CVS.com and Walgreens.com, the product is rolling out to stores nationwide in April and carries a suggested retail price of $39.99.
“Men have historically avoided this type of semen analysis because it can be embarrassing and inconvenient for them to go to a physician or lab for this type of test, yet approximately 50% of all infertility problems are directly attributed to the male, and most of them are mainly due to low sperm count,” SpermCheck CEO Ray Lopez said. “With such high incidence of fertility issues, coupled with low incidence of male testing, we saw a great opportunity to provide couples with an at-home test that can provide information that is crucial for conception preparation, yet takes the stigma out of the test, since it is done in the privacy of their own home.”
We're excited about the possibilities that SpermCheck has for couples who are struggling to conceive, and we hope it helps avoid expensive and embarrassing doctors visits. We also have a coupon on our website that you can redeem at Walgreens or Kinney Drugs for a few dollars off! http://www.spermcheck.com/